Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and Differences
- 1 October 2005
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 42, S3-S8
- https://doi.org/10.1053/j.seminhematol.2005.10.001
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationBritish Journal of Haematology, 2004
- JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) CellsJournal of Biological Chemistry, 2003
- Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivoLeukemia, 2003
- Molecular mechanisms of novel therapeutic approaches for multiple myelomaNature Reviews Cancer, 2002
- Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood, 2002
- Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applicationsLeukemia, 2001
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaBlood, 2001
- Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) CellsJournal of Biological Chemistry, 2001
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999